Reviews map the promise and limits of functional pet food ingredients

Two review articles are helping define the next phase of companion animal nutrition: a shift from broad “functional ingredients” language toward a more precise discussion of bioactive compounds, mechanisms, and evidence thresholds in commercial pet food. The headline finding isn’t that these ingredients are suddenly new, but that the science and the market are maturing faster than the terminology and clinical validation. The reviews suggest that ingredients such as polyphenols, plant extracts, fibers, microalgae-derived compounds, omega-3 sources, and cannabinoids are increasingly discussed as tools to support health beyond basic nutrient adequacy, but they also make clear that the supporting literature remains mixed and highly ingredient-specific. (mdpi.com)

That matters because the pet food sector has been moving in this direction for years. Commercial diets already include ingredients positioned around digestive health, skin and coat support, immune function, and healthy aging, while the supplement category has expanded even faster. AAFCO’s consumer guidance reflects how common these add-ins have become, from fiber sources such as chicory root and inulin to vitamin and mineral supplements, but the regulatory system still centers on ingredient safety, truthful labeling, and nutritional adequacy rather than broad therapeutic promises. FDA says substances added to pet food must either be approved food additives, be GRAS for the intended use, or otherwise fit within the legal framework for animal food ingredients. If a label crosses into claims to cure, treat, prevent, or mitigate disease, FDA may view it as a drug claim. (aafco.org)

The Veterinary Research Communications review appears aimed at exactly that gray zone. Based on the abstract and related indexing, the authors propose definitions and classification systems for functional ingredients, bioactive compounds, and dietary supplements in companion animals, borrowing in part from human nutrition frameworks. That’s important because inconsistent use of terms has made it hard to compare studies or translate findings into practice. The parallel Animals review narrows the lens to plant-derived ingredients and groups them by phytochemical class and application form, including direct supplementation and inclusion in complete diets. Its summary points to antioxidant, anti-inflammatory, immunomodulatory, and microbiome-related effects as the most commonly discussed mechanisms, with microalgae and omega-3 sources also linked to lipid metabolism, cardiovascular support, and skin integrity. (mdpi.com)

The broader literature supports that framing, but it also underscores the caveats. Reviews of plant extracts and nutraceuticals in dogs and cats repeatedly note potential benefits in gut health, redox balance, metabolism, and adjunctive support for chronic conditions, while also flagging recurring problems: small study sizes, short follow-up periods, inconsistent ingredient characterization, variable bioavailability, and limited standardization across products. Even within phytogenics, researchers have noted that failing to specify the exact form of an ingredient can make results difficult to interpret or reproduce. In other words, “contains botanicals” or “contains antioxidants” is rarely enough information for a clinician trying to evaluate likely effect in a patient. (mdpi.com)

Expert commentary from regulators and industry-facing guidance points in the same direction. FDA’s current animal food guidance emphasizes that intended use matters: an ingredient may be acceptable as a food component under one set of conditions, but not if it is positioned to prevent or treat disease. FDA has also encouraged companies developing novel animal foods with drug-like claims to engage with the agency earlier, reflecting growing pressure around products that blur the line between nutrition and therapy. For veterinarians, that’s a practical signal that the marketplace may continue to outpace the evidence, and that label language deserves close attention. (fda.gov)

Why it matters: In practice, these reviews give veterinary teams a more useful framework for discussing functional diets with pet parents. The key question isn’t whether functional ingredients exist in pet food. They clearly do. The harder question is which compounds have reproducible evidence, at what dose, in which species, in what formulation, and for what outcome. That distinction is especially important in dogs and cats with GI disease, dermatologic disease, obesity, osteoarthritis, cognitive aging, or multimorbidity, where pet parents may be drawn to “natural” or wellness-oriented products that sound evidence-based but may not have strong clinical data behind them. AAFCO itself notes that “natural” is a labeling term, not a safety or efficacy standard, and its supplement guidance stresses that combinations should be evaluated in the context of the animal’s baseline diet and safe use levels. (aafco.org)

For the profession, the likely takeaway is less about endorsing a category and more about raising the bar for evaluation. These reviews help organize a fast-growing field, but they also expose how much work remains on dose-response studies, long-term safety, species-specific outcomes, and clinically meaningful endpoints. Veterinary nutritionists and general practitioners may increasingly be asked to interpret not just nutrient profiles, but ingredient-level claims tied to microbiome modulation, inflammation, oxidative stress, or healthy aging. That makes evidence literacy, formulation scrutiny, and regulatory awareness more important than ever. (mdpi.com)

What to watch: The next phase will likely include more targeted formulation claims, more pressure for standardized ingredient definitions, and more interaction between manufacturers, AAFCO, and FDA over how novel functional ingredients can be marketed without crossing into drug claims. (fda.gov)